Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT).

摘要: Patients treated for a thoracic malignancy carry significant risk of developing other lung lesions. Locoregional control intrathoracic recurrences is challenging due to the impact prior therapies on normal tissues. We examined safety and efficacy re-irradiation using high-precision image-guided stereotactic body radiation therapy (SBRT). Records 39 patients with intra-thoracic conventionally fractionated (RT) who underwent SBRT subsequent primary, recurrent or metastatic tumor from 11/2004 7/2011 were retrospectively reviewed. Median dose RT was 61 Gy (range 30–80 Gy). biologically effective prescription (α/β = 10) (BED10) 70.4 42.6-180 With median followup 12.6 months among survivors, 1- 2-year actuarial local progression-free survival (LPFS) 77% 64%, respectively. recurrence-free (RFS) overall (OS) 13.8 22.0 months, without overlap high-dose regions primary plans more likely receive BED10 ≥100 Gy, which associated higher LPFS (hazard ratio, [HR] = 0.18, p = 0.04), RFS ([HR] = 0.31, p = 0.038) OS ([HR] = 0.25, p = 0.014). Grade 2 3 pulmonary toxicity observed in 18% 5% patients, Other grade 2–4 toxicities included chest wall pain 18%, fatigue 15% skin 5%. No 5 events occurred. can be safely successfully administered RT. Dose reduction cases direct successive fields results acceptable re-treatment profile.